MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.789
AS - Asia 8.995
EU - Europa 8.563
SA - Sud America 1.118
OC - Oceania 545
AF - Africa 414
Continente sconosciuto - Info sul continente non disponibili 13
Totale 38.437
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.108
GB - Regno Unito 2.961
SG - Singapore 1.962
CN - Cina 1.693
IT - Italia 1.319
HK - Hong Kong 912
VN - Vietnam 867
DE - Germania 847
BR - Brasile 791
SE - Svezia 632
PH - Filippine 557
AU - Australia 498
CA - Canada 479
TR - Turchia 469
FI - Finlandia 446
FR - Francia 437
RU - Federazione Russa 340
BD - Bangladesh 326
IR - Iran 288
IN - India 287
UA - Ucraina 287
KR - Corea 207
PK - Pakistan 191
ID - Indonesia 162
JP - Giappone 151
NL - Olanda 143
IE - Irlanda 139
BG - Bulgaria 119
ES - Italia 119
MY - Malesia 119
PL - Polonia 116
ZA - Sudafrica 113
AR - Argentina 109
MX - Messico 101
GR - Grecia 99
SA - Arabia Saudita 93
IQ - Iraq 87
IL - Israele 85
TW - Taiwan 85
MA - Marocco 77
BE - Belgio 71
AT - Austria 64
TH - Thailandia 59
NP - Nepal 58
AE - Emirati Arabi Uniti 57
EC - Ecuador 50
RO - Romania 49
LK - Sri Lanka 46
NZ - Nuova Zelanda 46
CO - Colombia 44
KE - Kenya 44
NO - Norvegia 44
JO - Giordania 43
GE - Georgia 39
EG - Egitto 38
CH - Svizzera 35
LT - Lituania 34
LV - Lettonia 34
CL - Cile 31
CZ - Repubblica Ceca 30
EE - Estonia 28
PT - Portogallo 28
HR - Croazia 25
NG - Nigeria 23
VE - Venezuela 22
BA - Bosnia-Erzegovina 21
TN - Tunisia 21
UZ - Uzbekistan 21
HU - Ungheria 20
PE - Perù 19
SI - Slovenia 18
DZ - Algeria 17
OM - Oman 17
PY - Paraguay 17
SK - Slovacchia (Repubblica Slovacca) 17
BO - Bolivia 14
BZ - Belize 14
UG - Uganda 14
BH - Bahrain 13
UY - Uruguay 13
JM - Giamaica 12
LB - Libano 12
PR - Porto Rico 12
AZ - Azerbaigian 11
CY - Cipro 10
DK - Danimarca 10
DO - Repubblica Dominicana 10
ET - Etiopia 10
CR - Costa Rica 9
MU - Mauritius 9
PA - Panama 9
PS - Palestinian Territory 9
KZ - Kazakistan 8
QA - Qatar 8
LY - Libia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
GY - Guiana 6
KG - Kirghizistan 6
MO - Macao, regione amministrativa speciale della Cina 6
Totale 38.295
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Ashburn 1.769
Southend 1.619
Santa Clara 1.391
Singapore 1.234
Woodbridge 1.143
Chandler 839
Houston 828
Hong Kong 813
Seattle 690
Wilmington 659
Cambridge 591
San Jose 542
Jacksonville 508
Dearborn 428
Ann Arbor 404
Nyköping 401
Beijing 375
Hefei 370
London 339
Los Angeles 335
Helsinki 332
Council Bluffs 289
Ho Chi Minh City 276
New York 275
Chicago 269
Hanoi 229
Modena 229
Frankfurt am Main 224
Redwood City 183
Munich 180
San Diego 178
The Dalles 163
Izmir 154
Milan 137
Seoul 129
Shanghai 121
Dallas 119
Princeton 116
Sofia 113
Salt Lake City 111
Melbourne 106
Buffalo 97
Eugene 96
Moscow 94
Lauterbourg 88
Jakarta 81
São Paulo 81
Dublin 76
Manchester 76
Sydney 76
Tokyo 74
Istanbul 71
Columbus 63
Ottawa 62
Brisbane 61
Bremen 59
Bologna 56
Phoenix 55
Elk Grove Village 53
Warsaw 53
Toronto 50
Tampa 47
Falls Church 46
Paris 46
Taipei 46
Rome 45
Montreal 44
Athens 43
Liverpool 43
Johannesburg 42
Da Nang 41
Brussels 40
Des Moines 40
Quezon City 39
Casablanca 38
Orem 38
Tehran 38
Atlanta 37
Fremont 37
Colombo 36
Miami 36
Karachi 35
Kuala Lumpur 35
Lahore 35
Riyadh 35
Denver 34
Dong Ket 34
Islamabad 34
Stockholm 34
Brooklyn 32
Cebu City 32
Manila 32
Perth 32
Amsterdam 31
Birmingham 31
Boston 31
Amman 30
Davao City 30
Riga 30
Totale 23.857
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.941
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 697
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 632
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 621
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 526
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 524
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 491
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 467
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 456
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 451
Empathic attitudes among nursing students: a preliminary study 412
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 412
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 406
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 390
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 388
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 383
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 378
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 375
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 369
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 369
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 366
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 364
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 362
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 359
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 356
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 349
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 346
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 343
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 336
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 335
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 333
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 332
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 322
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 322
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 316
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 315
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 315
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 313
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 312
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 311
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 310
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 308
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 307
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 307
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 306
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 304
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 304
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 303
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 303
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 302
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 302
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 301
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 300
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 300
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 300
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 299
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 293
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 288
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 288
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 287
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 286
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 284
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 283
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 278
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 278
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 277
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 275
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 275
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 272
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 270
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 265
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 264
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 258
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 252
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 250
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 249
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 244
Twenty-years experience with de novo metastatic breast cancer 243
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 242
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 241
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 239
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 235
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 234
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 229
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 224
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 223
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 222
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 220
I tumori nelle provincie di Parma, Reggio Emilia, Modena 219
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 210
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 208
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 207
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 205
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 200
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 195
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 191
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 186
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 185
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 183
Totale 37.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.823
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021250 0 0 0 0 0 0 0 0 0 0 0 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/202610.427 658 424 690 1.193 1.679 785 1.181 522 959 975 806 555
Totale 38.849